99059-14-0

Upstream product

• 5597-50-2 3-(4-hydroxyphenyl)propionic acid methyl ester 
• 67-66-3 chloroform 
• 501-97-3 4-hydroxyphenylpropionic acid 
• 100-97-0 hexamethylenetetramine 

Relevant academic research and scientific papers

Towards novel biolabels: Synthesis of a tagged highly fluorescent Schiff-base aluminium complex

Starting from 3-(4-hydroxyphenyl)propanoic acid, formylation ortho to the phenol and condensation with ortho-aminophenol gave a novel functionalised Schiff-base ligand. Formation of the N-hydroxysuccinimidyl ester and non-aqueous complexation with AlEt2Cl gave a novel fluorescent biolabel displaying a Stokes shift of 100 nm. The efficacy of the new system was demonstrated by its attachment to rabbit IgG.

Synthesis of HBED–CC–tris(tert-butyl ester) using a solid phase and a microwave reactor

N,N′-bis-[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N′-diacetic acid (HBED-CC) belongs to the acyclic, bifunctional complexing compounds used mainly for radiolabeling with gallium-68 (68Ga). Due to the high stability of the 68Ga3+complex, HBED-CC is well known for its rapid and efficient labeling at ambient temperature and the high stability of the complexes in vivo. The HBED-CC chelator in combination with a PSMA (Prostate Specific Membrane Antigen) inhibitor and labeled with isotope of gallium is an important tool for diagnosing the stage of cancer in patients with prostate cancer. Many HBED-CC derivatives have been described in the literature, but one of the most commonly used is 3-(3-{[(2-{[5-(2-tert-butoxycarbonylethyl)-2-hydroxybenzyl]-tert-butoxycarbonylmethylamino}-ethyl)-tert-butoxy-carbonylmethylamino]-methyl}-4-hydroxyphenyl)propionic acid (HBED–CC–tris(tert-butyl ester)). This compound is very expensive and commercially limited. Therefore this work describes an innovative method of synthesis on solid phase using of a microwave reactor. Optimization of the reaction allowed to obtain HBED-CC-tris(tert-butyl ester) with high purity and yield.

COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF

Provided are a compound including a cleavable linker, a use thereof, and an intermediate compound for preparing the same, and more particularly, the compound including a cleavable linker of the present invention may include an active agent (for example, a drug, a toxin, a ligand, a probe for detection, etc.) having a specific function or activity, a SO2 functional group which is capable of selectively releasing the active agent, and a functional group which triggers a chemical reaction, a physicochemical reaction and/or a biological reaction by external stimulation, and may further include a ligand (for example, oligopeptide, polypeptide, antibody, etc.) having binding specificity for a desired target receptor.

Identification of a New Class of Selective Excitatory Amino Acid Transporter Subtype 1 (EAAT1) Inhibitors Followed by a Structure-Activity Relationship Study

Screening of a small compound library at the three excitatory amino acid transporter subtypes 1-3 (EAAT1-3) resulted in the identification of compound (Z)-4-chloro-3-(5-((3-(2-ethoxy-2-oxoethyl)-2,4-dioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic aci

Inhibitors of protein kinase for the treatment of disease

The present invention is directed in part towards methods of modulating the function of protein kinases with phenol- and hydroxynaphthalene-based compounds. The methods incorporate cells that express a protein kinase. In addition, the invention describes methods of preventing and treating protein kinase-related abnormal conditions in organisms with a compound identified by the invention. Furthermore, the invention pertains to phenol- and hydroxynaphthalene-based compounds and pharmaceutical compositions comprising these compounds.